Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations

被引：0
|
作者：
Heymach, John
Opdam, Frans
Barve, Minal
Tu, Hai-Yan
Wu, Yi-Long
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yoh, Kiyotaka
Yamamoto, Noboru
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT203
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT203
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Wu, Y. L.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S1 - S1
  • [3] Updated data from the phase I Beamion Lung 1 trial of BI 1810631, a HER2 TKI, in patients (pts) with advanced solid tumours with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Tu, H-Y.
    Wu, Y-L.
    Gibson, N. J.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S63 - S64
  • [4] Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations
    Yamamoto, N.
    Opdam, F.
    Barve, M.
    Tu, H. -Y.
    Wu, Y. -L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S147 - S147
  • [5] Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
    Opdam, F.
    Heymach, J.
    Ruiter, G.
    Barve, M.
    Tu, H.
    Wu, Y-L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2023, 34
  • [6] A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    Yoh, K.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S421 - S422
  • [7] Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
    Heymach, John
    Yamamoto, Noboru
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Schroeter, Lukas
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Berz, David
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E1 - E1
  • [8] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Rohrbacher, Maren
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yamamoto, Noboru
    CLINICAL LUNG CANCER, 2023, 24 (02) : e65 - e68
  • [10] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S69 - S70
12345